Ann Arbor, MI, United States of America

Shelley Rene Graham

This inventor holds 1 USPTO granted patent. Top assignee: Pfizer Corporation. Active years: 2009.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shelley Rene Graham. Retrieved from https://idiyas.com/inventor/shelley-rene-graham

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2009

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Shelley Rene Graham: Innovator in Pain Treatment

Introduction

Shelley Rene Graham is a notable inventor based in Ann Arbor, MI (US). She has made significant contributions to the field of pain treatment through her innovative research and development.

Latest Patents

Shelley holds a patent for amino acid derivatives, which relates to a method of treating pain using a specific compound formula. This invention also includes novel derivatives that have potential applications in pain management.

Career Highlights

Shelley is currently employed at Pfizer Corporation, where she continues to advance her research in pharmaceuticals. Her work has been instrumental in developing new methods for pain relief.

Collaborations

Throughout her career, Shelley has collaborated with esteemed colleagues such as Simon John Mantell and David James Rawson. These partnerships have enhanced her research and contributed to her success in the field.

Conclusion

Shelley Rene Graham's innovative work in pain treatment exemplifies the impact of dedicated research and collaboration in the pharmaceutical industry. Her contributions continue to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…